165 related articles for article (PubMed ID: 33522595)
1. The design basis for the integrated and continuous biomanufacturing framework.
Coffman J; Bibbo K; Brower M; Forbes R; Guros N; Horowski B; Lu R; Mahajan R; Patil U; Rose S; Shultz J
Biotechnol Bioeng; 2021 Sep; 118(9):3323-3333. PubMed ID: 33522595
[TBL] [Abstract][Full Text] [Related]
2. A common framework for integrated and continuous biomanufacturing.
Coffman J; Brower M; Connell-Crowley L; Deldari S; Farid SS; Horowski B; Patil U; Pollard D; Qadan M; Rose S; Schaefer E; Shultz J
Biotechnol Bioeng; 2021 Apr; 118(4):1721-1735. PubMed ID: 33491769
[TBL] [Abstract][Full Text] [Related]
3. Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm.
Arnold L; Lee K; Rucker-Pezzini J; Lee JH
Biotechnol J; 2019 Feb; 14(2):e1800061. PubMed ID: 29729129
[TBL] [Abstract][Full Text] [Related]
4. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
5. Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales.
Hummel J; Pagkaliwangan M; Gjoka X; Davidovits T; Stock R; Ransohoff T; Gantier R; Schofield M
Biotechnol J; 2019 Feb; 14(2):e1700665. PubMed ID: 29341493
[TBL] [Abstract][Full Text] [Related]
6. Process intensification in fed-batch production bioreactors using non-perfusion seed cultures.
Yongky A; Xu J; Tian J; Oliveira C; Zhao J; McFarland K; Borys MC; Li ZJ
MAbs; 2019; 11(8):1502-1514. PubMed ID: 31379298
[TBL] [Abstract][Full Text] [Related]
7. End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies.
Mahal H; Branton H; Farid SS
Biotechnol Bioeng; 2021 Sep; 118(9):3468-3485. PubMed ID: 33792918
[TBL] [Abstract][Full Text] [Related]
8. Pilot-scale demonstration of an end-to-end integrated and continuous biomanufacturing process.
Coolbaugh MJ; Varner CT; Vetter TA; Davenport EK; Bouchard B; Fiadeiro M; Tugcu N; Walther J; Patil R; Brower K
Biotechnol Bioeng; 2021 Sep; 118(9):3287-3301. PubMed ID: 33410159
[TBL] [Abstract][Full Text] [Related]
9. A modular and multi-functional purification strategy that enables a common framework for manufacturing scale integrated and continuous biomanufacturing.
Pybus LP; Heise C; Nagy T; Heeran C; Dover T; Raven J; Kori J; Burton G; Sakuyama H; Hastings B; Lyons M; Nakai S; Haigh J
Biotechnol Prog; 2024 Mar; ():e3456. PubMed ID: 38494903
[TBL] [Abstract][Full Text] [Related]
10. Integrated continuous production of recombinant therapeutic proteins.
Warikoo V; Godawat R; Brower K; Jain S; Cummings D; Simons E; Johnson T; Walther J; Yu M; Wright B; McLarty J; Karey KP; Hwang C; Zhou W; Riske F; Konstantinov K
Biotechnol Bioeng; 2012 Dec; 109(12):3018-29. PubMed ID: 22729761
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for Comparison of Productivity Between Fed-Batch and Perfusion Processes.
Bausch M; Schultheiss C; Sieck JB
Biotechnol J; 2019 Feb; 14(2):e1700721. PubMed ID: 30024096
[TBL] [Abstract][Full Text] [Related]
12. A Different Perspective: How Much Innovation Is Really Needed for Monoclonal Antibody Production Using Mammalian Cell Technology?
Kelley B; Kiss R; Laird M
Adv Biochem Eng Biotechnol; 2018; 165():443-462. PubMed ID: 29721583
[TBL] [Abstract][Full Text] [Related]
13. Concentrated fed-batch cell culture increases manufacturing capacity without additional volumetric capacity.
Yang WC; Minkler DF; Kshirsagar R; Ryll T; Huang YM
J Biotechnol; 2016 Jan; 217():1-11. PubMed ID: 26521697
[TBL] [Abstract][Full Text] [Related]
14. Online monitoring and control of upstream cell culture process using 1D and 2D-LC with SegFlow interface.
Chemmalil L; Wasalathanthri DP; Zhang X; Kuang J; Shao C; Barbour R; Bhavsar S; Prabhakar T; Knihtila R; West J; Puri N; McHugh K; Rehmann MS; He Q; Xu J; Borys MC; Ding J; Li Z
Biotechnol Bioeng; 2021 Sep; 118(9):3593-3603. PubMed ID: 34185315
[TBL] [Abstract][Full Text] [Related]
15. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
Yang WC; Lu J; Kwiatkowski C; Yuan H; Kshirsagar R; Ryll T; Huang YM
Biotechnol Prog; 2014; 30(3):616-25. PubMed ID: 24574326
[TBL] [Abstract][Full Text] [Related]
16. Fully integrated downstream process to enable next-generation manufacturing.
Ramos I; Sharda N; Villafana R; Hill-Byrne K; Cai K; Pezzini J; Coffman J
Biotechnol Bioeng; 2023 Jul; 120(7):1869-1881. PubMed ID: 36950907
[TBL] [Abstract][Full Text] [Related]
17. Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies.
Schwarz H; Gomis-Fons J; Isaksson M; Scheffel J; Andersson N; Andersson A; Castan A; Solbrand A; Hober S; Nilsson B; Chotteau V
Biotechnol Bioeng; 2022 Aug; 119(8):2152-2166. PubMed ID: 35470430
[TBL] [Abstract][Full Text] [Related]
18. Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities.
Siganporia CC; Ghosh S; Daszkowski T; Papageorgiou LG; Farid SS
Biotechnol Prog; 2014; 30(3):594-606. PubMed ID: 24376262
[TBL] [Abstract][Full Text] [Related]
19. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.
Pollock J; Coffman J; Ho SV; Farid SS
Biotechnol Prog; 2017 Jul; 33(4):854-866. PubMed ID: 28480535
[TBL] [Abstract][Full Text] [Related]
20. Chemometrics and in-line near infrared spectroscopic monitoring of a biopharmaceutical Chinese hamster ovary cell culture: prediction of multiple cultivation variables.
Clavaud M; Roggo Y; Von Daeniken R; Liebler A; Schwabe JO
Talanta; 2013 Jul; 111():28-38. PubMed ID: 23622522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
